To develop criteria for the classification of fibromyalgia, we studied 558 consecutive patients: 293 patients with fibromyalgia and 265 control patients. Interviews and examinations were performed by trained, blinded assessors. Control patients for the group with primary fibromyalgia were matched for age and sex, and limited to patients with disorders that could be confused with primary fibromyalgia. Control patients for the group with secondary-concomitant fibromyalgia were matched for age, sex, and concomitant rheumatic disorders. Widespread pain (axial plus upper and lower segment plus left-and right-sided pain) was found in 97.6% of all patients with fibromyalgia and in 69.1% of all control patients. The combination of widespread pain and mild or greater tenderness in 2 11 of 18 tender point sites yielded a sensitivity of 88.4% and a specificity of 81

No abstract

No abstract

In sleep studies of (a) patients with the "fibrositis syndrome" and (b) healthy subjects undergoing stage 4 sleep deprivation, we observed in both groups the anomalous presence of alpha-rhythms in the non-rapid-eye-movement (NREM) sleep EEG. This phenomenon has been termed alpha-delta sleep. In the healthy subjects stage 4 deprivation was accompanied by the temporary appearance of muscoloskeletal and mood symptoms comparable to the symptoms seen chronically in the patients. It is suggested that the external arousing stimulus, which induced alpha-delta sleep in the subjects, is paralleled in the patients by an internal arousing mechanism. Such a mechanism, acting in competition with the NREM sleep system, would impair the presumed restorative function of NREM sleep and lead to the development of symptoms. It is proposed that the "fibrositis" symptom complex be considered a "non-restorative sleep syndrome". Evidence froms presented in support of the hypothesis that a disorder of serotonin metabolism serves as a basis for both the EEG sleep disturbance and the symptoms.

No abstract

No abstract

PAN and CSS differ in their morbidity and mortality; therefore, they should be considered as distinct clinical entities.

Seventeen patients with classic rheumatoid arthritis resistant to conventional therapy were treated in a double-blind, cross-over study with azathioprine (2.0 to 2.5 mg/kg/day) and placebo for two 16-week periods. Patients receiving azathioprine showed significant improvement in articular index, joint count, grip strength and effusions, manifest by 6 weeks but greater at 16 weeks. Erythrocyte sedimentation rate and latex titer did not change. White blood cell counts decreased on azathioprine, but normal counts did not preclude a response. Rash, nausea and hair thinning occurred in only 4 patients.There has been a recent resurgence in the use of the cytotoxic immunosuppressive agents in rheumatoid arthritis (1,2). Despite a relatively large clinical experience, only 3 studies can be considered to have been adequately controlled (3-5). The antimetabolite azathioprine which has been widely used in the field of homotransplantation has been shown to be beneficial, relatively safe and easy to manage. The present study was undertaken to assess the effectiveness of azathioprine (Imurana) in 17